Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shandong Weigao Group Medical Polymer Company Limited (SHWGF)
Weihai, CN
Shandong Weigao Group Medical Polymer Company Limited, established in Weihai, People's Republic of China, in 2000, operates as a comprehensive entity focused on the research, development, manufacturing, and sale of a wide array of medical devices, primarily single-use, across the PRC. The company's operations are structured into several distinct segments, including Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, and Blood Management Products. Its extensive product portfolio includes essential medical consumables such as infusion devices for both vascular and non-vascular access, infusion sets, syringes, puncture needles, and specialized clinical collection kits. Shandong Weigao also provides wound care solutions like sutures and healing dressings, alongside equipment for blood collection, storage, separation, and sterilization. Beyond these, the company's offerings encompass prefilled and pre-flush syringes, blood glucose testing devices, a full range of anesthesia consumables (general, local, and auxiliary), ICU equipment, and surgical instruments for both open and minimally invasive procedures. It is a key producer of orthopedic devices, instruments for tumor and blood vessel interventions, implantation materials, and artificial organs. Furthermore, the company manufactures medical PVC granules, various plastic packing materials, carton boxes, industrial automation equipment, molds, and hemodialysis equipment, encompassing Type I, Type II, and Type III medical devices. Complementing its core manufacturing, Shandong Weigao extends its services to finance leasing and factoring, wholesale distribution of various medical devices (including surgical and other disposable products), asset management, enterprise consulting, and logistics and storage. The company also engages in exporting its products, which are marketed under well-known brands such as Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing. Its diverse clientele includes hospitals, blood stations, other medical units, and distributors.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -0.43% | -39.73% | -36.23% | -36.23% | -42.11% | -74.57% | -79.15% | -21.43% | -82.19% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Instruments & Supplies: +7.9%-0.3% Q4'25: +4.8% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%-22.2% Q4'25: -26.8% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+9.3% Q4'25: +0.0% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+14.1% ★ Q4'25: +10.6% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+7.0% ★ Q4'25: +10.4% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.2% ★ Q4'25: +0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×2.15× ★ Q4'25: 1.26× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 1 EPS Ana. |
Dec 2027 10 Rev. Ana. 1 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.92B
est: 6.04B (-2.0%)
|
6.73B
est: 6.61B (+1.8%)
|
6.29B
est: 7.58B (-17.0%)
|
8.81B
est: 7.85B (+12.3%)
|
10.36B
est: 10.28B (+0.8%)
|
11.62B
est: 11.17B (+4.1%)
|
13.15B
est: 13.35B (-1.5%)
|
13.62B
est: 14.77B (-7.8%)
|
13.23B
est: 13.15B (+0.6%)
|
13.09B
est: 13.32B (-1.8%)
|
13.04B
est: 13.55B (-3.7%)
|
14.60B
14.43B – 14.73B
+7.7% YoY
|
15.50B
14.90B – 16.96B
+6.2% YoY
|
16.15B
15.74B – 17.01B
+4.2% YoY
|
| EBITDA |
1.70B
est: 1.73B (-1.8%)
|
1.72B
est: 1.89B (-8.9%)
|
1.91B
est: 2.17B (-11.7%)
|
2.62B
est: 2.24B (+16.9%)
|
3.27B
est: 2.94B (+11.1%)
|
3.09B
est: 3.19B (-3.2%)
|
3.75B
est: 3.82B (-1.7%)
|
4.38B
est: 4.22B (+3.7%)
|
3.55B
est: 3.76B (-5.5%)
|
3.78B
est: 3.67B (+2.8%)
|
2.79B
est: 3.73B (-25.3%)
|
4.02B
3.98B – 4.06B
+7.7% YoY
|
4.27B
4.11B – 4.67B
+6.2% YoY
|
4.45B
4.34B – 4.69B
+4.2% YoY
|
| EBIT |
1.38B
est: 1.34B (+2.7%)
|
1.21B
est: 1.47B (-17.7%)
|
1.55B
est: 1.69B (-8.2%)
|
2.06B
est: 1.75B (+18.0%)
|
2.65B
est: 2.29B (+15.8%)
|
2.40B
est: 2.49B (-3.3%)
|
3.02B
est: 2.97B (+1.5%)
|
3.58B
est: 3.29B (+8.9%)
|
2.64B
est: 2.93B (-9.7%)
|
2.80B
est: 2.79B (+0.5%)
|
1.83B
est: 2.84B (-35.4%)
|
3.05B
3.02B – 3.08B
+7.7% YoY
|
3.24B
3.12B – 3.55B
+6.2% YoY
|
3.38B
3.29B – 3.56B
+4.2% YoY
|
| Net Income |
1.11B
est: 1.21B (-8.2%)
|
1.11B
est: 1.16B (-4.4%)
|
1.30B
est: 1.48B (-11.8%)
|
1.47B
est: 1.42B (+3.9%)
|
1.84B
est: 1.93B (-4.4%)
|
2.09B
est: 2.10B (-0.8%)
|
2.28B
est: 2.48B (-8.3%)
|
2.76B
est: 2.66B (+3.9%)
|
2.00B
est: 2.00B (+0.2%)
|
2.07B
est: 2.05B (+0.7%)
|
1.57B
est: 1.98B (-20.9%)
|
1.76B
1.70B – 1.88B
-11.3% YoY
|
1.92B
1.85B – 2.05B
+8.9% YoY
|
1.99B
1.92B – 2.12B
+3.6% YoY
|
| SGA |
1.94B
est: 1.73B (+12.3%)
|
2.57B
est: 1.89B (+36.0%)
|
2.34B
est: 2.17B (+8.1%)
|
3.37B
est: 2.24B (+50.2%)
|
3.77B
est: 2.94B (+28.3%)
|
3.66B
est: 3.19B (+14.6%)
|
3.77B
est: 3.82B (-1.1%)
|
3.54B
est: 4.22B (-16.0%)
|
3.83B
est: 3.76B (+2.0%)
|
3.63B
est: 3.67B (-1.3%)
|
3.46B
est: 3.74B (-7.4%)
|
4.03B
3.98B – 4.06B
+7.7% YoY
|
4.28B
4.11B – 4.68B
+6.2% YoY
|
4.46B
4.34B – 4.69B
+4.2% YoY
|
| EPS |
0.25
est: 0.27 (-6.2%)
|
0.25
est: 0.25 (-1.7%)
|
0.29
est: 0.32 (-10.7%)
|
0.33
est: 0.31 (+5.9%)
|
0.41
est: 0.42 (-3.4%)
|
0.46
est: 0.46 (-0.5%)
|
0.51
est: 0.55 (-6.5%)
|
0.61
est: 0.58 (+4.3%)
|
0.44
est: 0.44 (+0.2%)
|
0.46
est: 0.45 (+1.7%)
|
0.35
est: 0.44 (-20.0%)
|
0.39
0.37 – 0.41
-11.3% YoY
|
0.42
0.41 – 0.45
+8.9% YoY
|
0.44
0.42 – 0.47
+3.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jing Long | Executive Chairman of the Board & Compliance Officer | 428.8K | male |
| Rinan Cong | Chief Executive Officer & Executive Director | 303.4K | male |
| Daoming Wang | Executive Director | 99.0K | male |
| Junqiang Lu | Executive Director | 99.0K | male |
| Miu Ling Wong | Company Secretary | — | female |
| Xue Feng Wu | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SHWGF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
